HK1257566A1 - Bace1抑制劑 - Google Patents
Bace1抑制劑Info
- Publication number
- HK1257566A1 HK1257566A1 HK18116651.6A HK18116651A HK1257566A1 HK 1257566 A1 HK1257566 A1 HK 1257566A1 HK 18116651 A HK18116651 A HK 18116651A HK 1257566 A1 HK1257566 A1 HK 1257566A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bace
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16158075 | 2016-03-01 | ||
PCT/EP2017/054541 WO2017148878A1 (en) | 2016-03-01 | 2017-02-28 | Bace 1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257566A1 true HK1257566A1 (zh) | 2019-10-25 |
Family
ID=55453071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116651.6A HK1257566A1 (zh) | 2016-03-01 | 2018-12-27 | Bace1抑制劑 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20190055231A1 (zh) |
EP (1) | EP3423450B1 (zh) |
JP (1) | JP6616525B2 (zh) |
CN (1) | CN108699051B (zh) |
AR (1) | AR107752A1 (zh) |
HK (1) | HK1257566A1 (zh) |
TW (1) | TWI644913B (zh) |
WO (1) | WO2017148878A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210003872A (ko) | 2018-04-27 | 2021-01-12 | 시오노기 앤드 컴파니, 리미티드 | 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012095469A1 (en) | 2011-01-13 | 2012-07-19 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
WO2014065434A1 (en) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014114532A1 (en) * | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
US9296734B2 (en) * | 2013-03-01 | 2016-03-29 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
BR112015019412A8 (pt) * | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016001266A1 (en) * | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
-
2017
- 2017-02-28 EP EP17706829.3A patent/EP3423450B1/en active Active
- 2017-02-28 US US16/077,803 patent/US20190055231A1/en not_active Abandoned
- 2017-02-28 CN CN201780014746.XA patent/CN108699051B/zh active Active
- 2017-02-28 WO PCT/EP2017/054541 patent/WO2017148878A1/en active Application Filing
- 2017-02-28 JP JP2018545835A patent/JP6616525B2/ja not_active Expired - Fee Related
- 2017-03-01 AR ARP170100493A patent/AR107752A1/es unknown
- 2017-03-01 TW TW106106647A patent/TWI644913B/zh not_active IP Right Cessation
-
2018
- 2018-12-27 HK HK18116651.6A patent/HK1257566A1/zh unknown
-
2020
- 2020-12-16 US US17/123,375 patent/US20210101894A1/en not_active Abandoned
-
2022
- 2022-06-02 US US17/830,894 patent/US20220298152A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR107752A1 (es) | 2018-05-30 |
JP2019507164A (ja) | 2019-03-14 |
EP3423450B1 (en) | 2019-11-27 |
TW201734010A (zh) | 2017-10-01 |
US20190055231A1 (en) | 2019-02-21 |
CN108699051B (zh) | 2021-12-24 |
JP6616525B2 (ja) | 2019-12-04 |
CN108699051A (zh) | 2018-10-23 |
US20220298152A1 (en) | 2022-09-22 |
EP3423450A1 (en) | 2019-01-09 |
US20210101894A1 (en) | 2021-04-08 |
WO2017148878A1 (en) | 2017-09-08 |
TWI644913B (zh) | 2018-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283267A (en) | Inhibitors of menin–mll interaction | |
IL264687B (en) | cdk2/4/6 pyridopyrimidinone inhibitors | |
DK3478217T3 (en) | Historisk scanningsreference for intraorale scanninger | |
PL3512850T3 (pl) | Inhibitory interakcji menina-mll | |
AU201616677S (en) | Cylindres | |
GB201507594D0 (en) | Intamac 1 | |
GB201521134D0 (en) | Privitar case 1 | |
IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
PL3509789T3 (pl) | Urządzenie do obróbki | |
GB201612860D0 (en) | Inhibitors | |
HK1257566A1 (zh) | Bace1抑制劑 | |
GB201608438D0 (en) | Component Manuafacturing | |
GB2546509B (en) | Component | |
GB201621147D0 (en) | Tidysqueeze 5 | |
AU5457P (en) | JOAe 6656 Aeonium arborium | |
GB201621467D0 (en) | Modified bulgeomers | |
GB201607697D0 (en) | OverTyre 1 | |
AU201616673S (en) | tallboy | |
GB201616374D0 (en) | Modified bulgeomers | |
GB201614858D0 (en) | Modified Bulgeomers | |
GB201601798D0 (en) | Rollette 2 | |
GB201600933D0 (en) | Pantrap 2016 | |
AP2016001138S (en) | Chisa kooka | |
GB201603079D0 (en) | X block | |
AU2016162V (en) | Kingscawite Scaevola aemula |